Replimune Group, Inc. (REPL) Stock Analysis — Probabli.AI
AI-powered analysis for REPL (Replimune Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Neutral.
Last price: $11.47 · Market cap: $972.0M · AI outlook: Neutral
Replimune Group, Inc., currently priced at $11.47, is showing promising developments in its oncolytic virus therapy pipeline, supported by positive trial results and significant funding. However, regulatory challenges and cautious analyst sentiment present headwinds. The stock's one-year outlook is moderately cautious, given current assessments, but there are substantial long-term growth…
Probabilistic 1-Year Outlook
- Bull 20% · Neutral 50% · Bear 30%
- 1-year price estimates — P10: $9 / P50: $10 / P90: $14
- Replimune's recent positive headlines surrounding its pipeline and funding provide optimism. However, the analyst consensus and price targets suggest caution. The regulatory setback reported is a potential downside…
5-Year Outlook
- Bull 35% · Neutral 40% · Bear 25%
- 5-year price estimates — P10: $9 / P50: $20 / P90: $35
SWOT Highlights
- Strength: Promising pipeline in oncolytic virus therapy
- Strength: Recent positive trial results
- Risk: Regulatory setbacks
- Risk: Current negative EPS surprise history
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
8 Wall Street analysts rate REPL a HOLD with a mean price target of $9.6.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
REPL forecast details · REPL sentiment details · REPL insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.